Eli Lilly and Company (LLY)vsAlpha Teknova Inc (TKNO)
LLY
Eli Lilly and Company
$1,164.79
+1.04%
HEALTHCARE · Cap: $994.92B
TKNO
Alpha Teknova Inc
$8.34
+7.06%
HEALTHCARE · Cap: $418.23M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 182202% more annual revenue ($79.67B vs $43.70M). LLY leads profitability with a 33.5% profit margin vs -38.4%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
TKNO
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
18.5% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : TKNO
The strongest argument for TKNO centers on Revenue Growth. Revenue growth of 18.5% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
TKNO carries more volatility with a beta of 0.73 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 24/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology industry, specializing in the development of essential biological reagents and supplements that facilitate advancements in life sciences research and biomanufacturing. The company's innovative offerings are integral to high-demand sectors, including vaccine development, cell and gene therapy, and diagnostic testing, underscoring its commitment to quality and superior customer support. With a robust biotechnology foundation and a focus on innovation, Alpha Teknova is well-positioned to capitalize on growth opportunities within the rapidly evolving life sciences market, enhancing its appeal to institutional investors seeking strategic investments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?